Marker Therapeutics Inc (MRKR)

[poods]

The reason I'm invested in marker is quite simple. I think the evidence for activity for Multi-TAA is essentially unassailable in hematological malignancy and suggested but not yet confirmed for pancreatic cancer. With the low cost and absence of side effects, I just don't see how Multi-TAA cannot become an important addition to many cancer treatment regimens, particularly combination treatments. If immunotherapy is ever going to work for the majority of patients, it will likely take multi-targeted strategies, without compiling side effects. Multi-TAA fills that niche beautifully. We now know it can be used with a multi-dosing strategy with chemotherapy and chemotherapy apparently does not suppress in vivo expansion or epitope spreading, or at least suppression can be compensated for with multi-dosing. We don't know yet how this will perform with checkpoint blockade, but it certainly makes sense to expect some degree of synergism. I think it's time for a full court press and if raising capital is the problem because the market has not rewarded MRKR with a reasonable SP, the CEO should immediately pursue one or more strategic partnerships. I'd be surprised if he is not already doing so.